Rafael Martinez, MD
Pulmonary Disease · Tampa, FLNPI 1629144795
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $25,047 of the $37,398 with a category attached, or 67.0%. 58 manufacturers reported payments, led by Intuitive Surgical at 32.9% of the total. Reporting peaked in 2023 at $16,182 and has fallen 74.0% since, to $4,200 in 2025. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,290 payments — averaging $28.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$12K
- GSK$5K
- AstraZeneca$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Boehringer Ingelheim$1K
- Harmony Biosciences LLC$1K
- plus $13K from 52 others
Across 216 payments — averaging $4070.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$228K
- E.r. Squibb & Sons, L.L.C.$207K
- Roche Products Limited$173K
- Boehringer Ingelheim$115K
- Insmed, Inc.$68K
- CSL Behring$60K
- plus $27K from 6 others
What the payments were for
- Food & beverage$25,04767%
- Education$12,35133%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,000
- ION$3,000
- TRELEGY ELLIPTA$356
- BREZTRI$224
- PURIFIED CORTROPHIN GEL$182
- AIRSUPRA$106
- TEZSPIRE$106
- FASENRA$106
How this compares
$37,398 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 119 | $1,546,010 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 2,001 | $1,520,282 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 897 | $638,434 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 53 | $565,407 |
| Spiriva RespimatTiotropium Bromide | 685 | $445,136 |
| Dupixent SyringeDupilumab | 98 | $399,086 |
| GlassiaAlpha-1-Proteinase Inhibitor | 35 | $397,615 |
| XolairOmalizumab | 63 | $302,173 |
| Dupixent PenDupilumab | 74 | $292,704 |
| SymbicortBudesonide/Formoterol Fumarate | 1,095 | $288,586 |
| Breo ElliptaFluticasone/Vilanterol | 578 | $265,107 |
| XywavSodium,calcium,mag,pot Oxybate | 12 | $244,190 |
| Spiriva HandihalerTiotropium Bromide | 180 | $157,829 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 246 | $134,046 |
| NucalaMepolizumab | 33 | $129,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,374 | $2,205,4621,193 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $4,787 | $2,087,5702,981 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Tezspire, Fasenra | $3,165 | $1,183,9322,045 claims |
| Grifols USA, LLCProlastin C | $1,060 | $565,40753 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $2,075 | $397,61535 claims |
| PfizerEliquis | $107 | $39,63649 claims |
| MerckDulera, Belsomra | $55 | $34,30778 claims |
| Lilly USA, LLCMounjaro | $36 | $14,27213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Tampa
- Ricardo Restrepo-JaramilloTampa$555K
- Mark RumbakTampa$528K
- Domenick ReinaTampa$469K
- Michael AlvarezTampa$202K
- Nirav PatelTampa$105K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
- Jennifer FultonJacksonville$665K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.